Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: Systematic review and meta-analysis

Leukemia and Lymphoma

Volumn 50, Issue 5, 2009, Pages 764-772

  Raanani, Pia ^a   Gafter Gvili, Anat ^a,b   Paul, Mical ^a,b   Ben Bassat, Isaac ^b   Leibovici, Leonard ^a   Shpilberg, Ofer ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chronic lymphocytic leukemia; Immunoglobulin prophylaxis; Lymphoproliferative disorders; Multiple myeloma; Plasma cell disorders

Indexed keywords

CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MELPHALAN; PLACEBO; PREDNISONE; STEROID; VINCRISTINE;

ALLERGIC REACTION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOPROPHYLAXIS; INFECTION; INFECTION PREVENTION; INFECTION RISK; META ANALYSIS; MULTIPLE MYELOMA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFECTION; INFECTION CONTROL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MULTIPLE MYELOMA; PREMEDICATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 68449089448     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902856824     Document Type: Article

References (20)

1. Co-operative Group for the Study of Intravenous Immunoglobulin. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988;319:902-907.
2. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994;343:1059-1063.
3. Anonymous. Consensus on IVIG. Lancet 1990;336:470-472.
4. Chapel HM, Lee M. The use of intravenous immune globulin in multiple myeloma. Clin Exp Immunol 1994;97(Suppl 1): 21-24.
5. Higgins JPT, Greene R. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. Vol. 4. Chichester, UK: John Wiley & Sons Ltd.; 2006.
6. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
7. Chapel H, Griffiths H, Brennan V, Bunch C, Lea J, Lee M. Hypogammaglobulinaemia in low grade B cell tumours; significance and therapy. Immunol Invest 1991;20:187-191.
8. Chapel HM, Hargreaves R, Lee M, Pamphilon D. Intravenous immunoglobulin therapy in patients with multiple myeloma. Immunodeficiency 1993;4:77-78.
9. Gamm H, Huber C, Chapel H, Lee M, Ries F, Dicato MA. Intravenous immune globulin in chronic lymphocytic leukaemia. Clin Exp Immunol 1994;97(Suppl 1):17-20.
10. Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989;73:366-368.
11. Salmon SE, Samal BA, Hayes DM, Hosley H, Miller SP, Schilling A. Role of δ globulin for immunoprophylaxis in multiple myeloma. N Engl J Med 1967;277:1336-1340.
12. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991;325:81-86.
13. Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 1995;17:75-80.
14. Chapel H, Dicato M, Gamm H, Brennan V, Ries F, Bunch C, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: A comparison of two dose regimes. Br J Haematol 1994;88:209-212.
15. Gluck S, Schnutenhaus W, Schneider W. Prophylactic intravenous immunoglobulin (IVIG) application to patients with recurrent infections and secondary antibody deficiency due to B-cell neoplasia. Blut 1990;61:140.
16. Hargreaves RM. Infection, immune responses and intravenous immunoglobulin infection prophylaxis in myeloma. Br J Cancer 1992;66:11.
17. Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996; 81:121-126.
18. Musto P, Brugiatelli M, Carotenuto M. Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma. Br J Haematol 1995;89:945-946.
19. Sklenar I, Schiffman G, Jonsson V, Verhoef G, Birgens H, Boogaerts M, et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Oncology 1993;50:466-477.
20. Ludwig H, Zojer N. Supportive care in multiple myeloma. Best Pract Res Clin Haematol 2007;20:817-835.